engine
Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal
Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine